Breaking News Instant updates and real-time market news.

VRAY

ViewRay

$3.40

0.08 (2.41%)

, ARDX

Ardelyx

$7.24

-0.2 (-2.69%)

19:00
12/02/19
12/02
19:00
12/02/19
19:00

Fly Intel: After Hours Movers

HIGHER: Viewray (VRAY) up 29.4% after disclosing collaboration and investment from Elekta and Medtronic... Ardelyx (ARDX) up 10.5% after announcing Phase 3 conference call on tenapanor in CKD... Puma Biotechnology (PBYI) up 7.2% after getting Nerlynx marketing approval in Singapore... Aldeyra Therapeutics (ALDX) up 6.9% after announcing conference call on Phase 3 results for topical ocular reproxalap ... Ready Capital (RC) up 5.4% after entering S&P SmallCap600 index. DOWN AFTER EARNINGS: Coupa Software (COUP) down 3.0%. ALSO LOWER: Plugpower (PLUG) down 8.7% after equity offering... Kodiak Sciencies (KOD) down 8.0% after equity offering... Karuna Therapeutics (KRTX) down 5.1% after disclosing board member resignation... Clarivate (CCC) down 4.4% after equity offering... Tufin Software (TUFN) down 4.1% after equity offering... Arrowhead Pharma (ARWR) down 2.7% after equity offering... Clearway Energy (CWEN) down 2.1% after equity offering. Movers as of 18:30ET.

VRAY

ViewRay

$3.40

0.08 (2.41%)

ARDX

Ardelyx

$7.24

-0.2 (-2.69%)

PBYI

Puma Biotechnology

$10.72

1.27 (13.44%)

ALDX

Aldeyra

$7.50

-0.445 (-5.60%)

RC

Ready Capital

$15.73

-0.01 (-0.06%)

COUP

Coupa Software

$148.98

-4.4 (-2.87%)

PLUG

Plug Power

$3.79

-0.11 (-2.82%)

KOD

Kodiak Sciences

$51.09

21.39 (72.02%)

KRTX

Karuna Therapeutics

$75.77

3.02 (4.15%)

CCC

Clarivate Analytics

$17.92

-0.08 (-0.44%)

TUFN

Tufin

$19.07

-0.13 (-0.68%)

ARWR

Arrowhead

$63.33

-9.65 (-13.22%)

CWEN

Clearway Energy

$19.28

0.09 (0.47%)

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 17

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

VRAY ViewRay
$3.40

0.08 (2.41%)

10/21/19
OPCO
10/21/19
INITIATION
Target $7
OPCO
Outperform
ViewRay initiated with an Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target.
10/15/19
PIPR
10/15/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay preannounced better than expected Q3, says Piper Jaffray
ViewRay this morning preannounced better than expected Q3 sales results after installing three systems compared to the Street estimate at two, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Further, the eight MRIdian system orders in Q3, including three upgrades, were in-line with expectations and a "welcome sight" as investors had worried that hesitancy around the proposed reimbursement bundle would result in significant delays in purchasing decisions, adds the analyst. He views the results as "largely positive" and reiterates an Overweight rating on ViewRay shares with a $6 price target. O'Brien, who admits the company's cash burn was a little higher than he had modeled, sees a "compelling entry point" at current ViewRay share levels.
09/16/19
PIPR
09/16/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay recent orders 'incremental positives,' says Piper Jaffray
ViewRay this morning announced that Penn State Health has entered a master agreement to purchase up to four MRIdian systems with the immediate order of one system and the ability to order an additional three systems in the future, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This news follows an announcement last Thursday of an MRIdian order from Stanford Health Care, adds the analyst. He views these orders as "incremental positives" and further evidence of the "unique capabilities" of the MRIdian system. O'Brien reiterates an Overweight rating on ViewRay with a $6 price target.
10/21/19
OPCO
10/21/19
INITIATION
Target $7
OPCO
Outperform
Oppenheimer starts ViewRay with Outperform rating, $7 price target
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target. The promise of ViewRay's technology is in superior outcomes and lower toxicity, says Kalia, who estimates that 20%-30% of all medical linear accelerators placed within ten years will have magnetic resonance-guided capabilities. "We are in the first innings of a highly disruptive technology adoption curve," Kalia tells investors in a research note.
ARDX Ardelyx
$7.24

-0.2 (-2.69%)

09/03/19
PIPR
09/03/19
NO CHANGE
Target $15
PIPR
Overweight
Ardelyx trial results a 'home run,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he is incrementally positive on Ardelyx and expects the shares to move up "sharply" after the company reported top-line data on lead drug tenapanor's AMPLIFY trial. The "home run" trial results showed that not only can adding tenapanor to a binder lower serum phosphorus significantly, it can do so relatively safely, said Raymond, who expects results from tenapanor's second Phase 3 pivotal trial by year-end and an NDA submission early next year. He keeps an Overweight rating and $15 price target on Ardelyx shares, which are up 15% to $3.92 in early trading.
09/09/19
PIPR
09/09/19
NO CHANGE
Target $15
PIPR
Overweight
Piper still sees 'substantial upside' in Ardelyx despite last week's rally
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations, the market still hasn't grasped tenapanor's full market potential in the renal setting, Raymond tells investors in a research note. Feedback from a recent nephrologist survey indicates "significant" awareness, interest and willingness to prescribe tenapanor, adds the analyst. He sees the drug's revenue potential "at well" over $1B in the U.S. alone. As such, Raymond continues to view his $15 target as a "more appropriate valuation" than current share levels. He maintains an Overweight rating on Ardelyx.
09/12/19
PIPR
09/12/19
NO CHANGE
Target $15
PIPR
Overweight
Piper says Ardelyx IBS-C nod de-risks 'real value driver' of hyperphosphatemia
After Ardelyx announced that the FDA has approved Ibsrela for the treatment of irritable bowel syndrome with constipation, or IBS-C, Piper Jaffray analyst Christopher Raymond said he does not model any value from this indication, but he sees the approval "materially de-risking" approval for hyperphosphatemia, which he views as the "real value driver" for Ardelyx. The analyst, who still sees a significant disconnect between tenapanor's potential in the renal space and the market's current view, despite the stock's 114% quarter-to-date advance, keeps an Overweight rating on Ardelyx shares with a $15 price target.
10/17/19
PIPR
10/17/19
NO CHANGE
Target $15
PIPR
Overweight
Ardelyx story remains 'grossly underappreciated,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he came away from the analyst day held by Ardelyx "increasingly comfortable" that management can fully exploit tenapanor's differentiation "as the first true advance in the phosphate lowering category in the renal setting in a couple of decades" and he is also "increasingly confident" in his $15 price target for the shares. Tenapanor's unique mechanism of action is "appreciated by nephrologists but still lost on the Street," contends the analyst, who sees the stock as "grossly underappreciated" and maintains an Overweight rating.
PBYI Puma Biotechnology
$10.72

1.27 (13.44%)

11/07/19
LEHM
11/07/19
NO CHANGE
Target $6
LEHM
Underweight
Puma Biotechnology price target lowered to $6 from $9 at Barclays
Barclays analyst Gena Wang lowered her price target for Puma Biotechnology to $6 from $9 and keeps an Underweight rating on the shares. Puma reported Q3 Nerlynx revenue of $53.6M, below the consensus of $59.0M, and lowered its 2019 guidance for the second time to $205M-$210M from $220M-$240M, Wang tells investors in a research note. The analyst continues to see a limited growth outlook in extended adjuvant setting as well as metastatic HER2+ breast cancer.
10/21/19
GSCO
10/21/19
NO CHANGE
GSCO
Sell
Goldman says Seattle Genetics' positive results affirm narrower Puma opportunity
Goldman Sachs analyst Paul Choi said Seattle Genetics' (SGEN) positive top-line results from its HER2CLIMB trial of tucatinib in HER2+ breast cancer patients likely affirm a narrower metastatic opportunity for Puma Biotechnology's (PBYI) Nerlynx. Nerlynx will have a first-mover advantage, acknowledges Choi, but he continues to expect low market penetration based on its side effects and lack of an OS benefit, leading him to maintain a Sell rating on Puma shares.
11/08/19
CANT
11/08/19
NO CHANGE
Target $14
CANT
Neutral
Puma Biotechnology price target lowered to $14 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young lowered her price target for Puma Biotechnology to $14 from $20 saying she's more cautious on the long-term revenue outlook for Nerlynx following the company's Q3 results. The analyst reiterates a Neutral rating on the shares.
11/07/19
RBCM
11/07/19
NO CHANGE
Target $13
RBCM
Sector Perform
Puma Biotechnology price target lowered to $13 from $23 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Puma Biotechnology to $13 and kept his Sector Perform rating after its Q3 results showed a miss on Nerlynx sales. The analyst warns that the print may reflect lower demand due to dose-reductions, also noting his lowered estimates in late-stage metastatic breast cancer where he sees greater competitive pressure from other HER2+ agents in that setting.
ALDX Aldeyra
$7.50

-0.445 (-5.60%)

06/26/19
SBSH
06/26/19
NO CHANGE
Target $24
SBSH
Buy
Aldeyra selloff on SOLACE trial failure presents buying opportunity, says Citi
After Aldeyra reported the failure of its SOLACE trial in non-infectious anterior uveitis, Citi analyst Yigal Nochomovitz noted that potential use of the drug contributed only about 10% of his peak revenue estimate and removing it from his estimates reduced his price target on the stock to $24 from $28. However, he believes that read-through to its dry eye disease and allergic conjunctivitis programs should be minimal and he views yesterday's selloff as a good buying opportunity. Nochomovitz keeps a Buy rating on Aldeyra shares.
06/26/19
ADAM
06/26/19
NO CHANGE
Target $20
ADAM
Buy
SOLACE fails but RENEW trial remains key for Aldeyra, says Canaccord
Canaccord analyst John Newman noted Aldeyra's Phase 3 SOLACE study did not show statistical significance for non-anterior uveitis but he said the company's focus remains its RENEW trial for dry eye. The analyst removed revenues for the non-infectious anterior uveitis as development will be discontinued. Newman reiterated his Buy rating and $20 price target on Aldeyra shares
10/14/19
ROTH
10/14/19
NO CHANGE
ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Commenting on the Ophthalmology space, Roth Capital analyst Zegbeh Jallah highlights her conviction for stronger valuations, driven by the increasing number of companies with innovative pipelines, and pending changes at both the FDA and CMS. The analyst suspects that these changes could lead to more wins in the space, which could drive valuations. Further, she cautions investors to keep "their eyes peeled on developments in the space." Jallah sees this as possible relevant for KalVista (KALV), Regenxbio (RGNX), Kala Pharmaceuticals (KALA), Kodiak Sciences (KOD), Regeneron (REGN), Aerie Pharmaceuticals (AERI), Applied Genetic (AGTC), Aldeyra (ALDX), Adverum Biotechnologies (ADVM), Clearside Biomedical (CLSD), Ocugen (OCGN), and many others.
10/22/19
CANT
10/22/19
INITIATION
Target $33
CANT
Overweight
Aldeyra assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen assumed coverage of Aldeyra with an Overweight rating and $33 price target. The peak sales potential of the company's "deep and innovative" pipeline that is focused on immune-mediated diseases is underappreciated, says the analyst. She expects upward earnings revisions to drive the shares higher.
RC Ready Capital
$15.73

-0.01 (-0.06%)

11/08/19
COMP
11/08/19
DOWNGRADE
Target $16.5
COMP
Hold
Ready Capital downgraded to Hold from Buy at Compass Point
Compass Point analyst Scott Valentin downgraded Ready Capital to Hold from Buy with a $16.50 price target.
COUP Coupa Software
$148.98

-4.4 (-2.87%)

10/29/19
PIPR
10/29/19
INITIATION
Target $150
PIPR
Overweight
Piper starts Coupa at Overweight, says sales could triple by 2024
Piper Jaffray analyst Brent Bracelin last night initiated coverage of Coupa Software with an Overweight rating and $150 price target. Modern software to manage, monitor, and optimize business spend management in real-time addresses a large $56B total addressable market cross 100,000-plus potential customers, Bracelin tells investors in a research note. Further, he believes Coupa Pay could further enhance the company's growth and margins. Coupa's revenue could triple to $1.45B by 2024, says the analyst.
10/28/19
PIPR
10/28/19
INITIATION
Target $150
PIPR
Overweight
Coupa Software initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Brent Bracelin initiated coverage of Coupa Software with an Overweight rating and $150 price target.
10/25/19
SBSH
10/25/19
INITIATION
Target $141
SBSH
Neutral
Coupa Software initiated with a Neutral at Citi
Citi analyst Daniel Jester initiated coverage of Coupa Software with a Neutral rating and $141 price target.
10/16/19
JMPS
10/16/19
NO CHANGE
Target $225
JMPS
Outperform
JMP says Workday discussed Coupa's success in Procurement at analyst day
JMP Securities analyst Patrick Walravens said his five key takeaways from Workday's (WDAY) analyst day event were the company's guiding to the high end of its guidance range for total revenue and subscription revenue; its expanding customer base; the fact that its largest near-term add-on opportunities are in Financials, Planning, Prism analytics, and Learning products; the CEO's statement that he views Procurement and Spend Management as an important category, citing the success that Coupa (COUP) has had; and the company's success moving its Financial Management products upstream to larger enterprise customers. Following the event, Walravens keeps an Outperform rating and $225 price target on Workday shares.
PLUG Plug Power
$3.79

-0.11 (-2.82%)

11/11/19
11/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wayfair (W) upgraded to Buy from Hold at Argus with analyst Jim Kelleher saying the recent "sharp pullback" in the stock price offers a favorable entry point, with added benefits expected if U.S. and China can reach a "phase 1" trade agreement, since about 60% of its products are made in China. 2. Q2 Holdings (QTWO) upgraded to Buy from Neutral at BTIG with analyst Mark Palmer saying the recent pullback in the stock price offers an attractive entry point given the company's takeout target potential. 3. Plug Power (PLUG) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin citing visibility for the company continuing on impressive growth trajectory, outlook for record revenue and EBITDA in Q4, and material EBITDA profitability in 2020. 4. Alliance Data (ADS) upgraded to Outperform from Perform at Oppenheimer with analyst Dominick Gabriele saying he sees the card services segment net of corporate drag as worth at least $119 using a 2.95x P/TBV multiple, and total Alliance Data including LoyaltyOne could be worth $131. 5. Oshkosh (OSK) upgraded to Buy from Neutral at Buckingham with analyst Neil Frohnapple saying his firm recently completed its monthly equipment rental rate momentum survey and says that overall, 52% of contacts surveyed noted that rental rates were above their expectations in the month of October. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/19
ROTH
11/11/19
UPGRADE
ROTH
Buy
Plug Power upgraded to Buy from Neutral at Roth Capital
Roth Capital analyst Craig Irwin upgraded Plug Power to Buy from Neutral.
11/11/19
ROTH
11/11/19
UPGRADE
Target $6
ROTH
Buy
Plug Power passing an inflection point, says Roth Capital
Roth Capital analyst Craig Irwin upgraded Plug Power to Buy from Neutral with a price target of $6, up from $3, citing visibility for the company continuing on impressive growth trajectory, outlook for record revenue and EBITDA in Q4, and material EBITDA profitability in 2020. In a research note to investors, Irwin says he believes the company is passing an inflection point and the upgrade acknowledges the longer-term potential serving the opportunity in lift trucks and adjacent markets.
11/25/19
RILY
11/25/19
NO CHANGE
Target $6
RILY
Buy
Plug Power price target raised to $6 from $3.50 at B. Riley FBR
B. Riley FBR analyst Christopher Van Horn raised his price target for Plug Power to $6 from $3.50 and reiterates a Buy rating on the shares. The stock closed Friday at $3.38. The company's long-term revenue target of $1B over the next five years, with $200M in adjusted EBITDA, "seems highly probable," given recent industry- and company-specific fundamentals, Van Horn tells investors in a research note. Based on recent award activity and market commentary, the analyst believes the stock and the fuel cell technology seem to be at an inflection point. He sees "strengthening demand" for its technology in core material handling markets, as well as lateral opportunities in on-road applications. Plug Power is better positioned in its core material handling business than ever before, contends Van Horn.
KOD Kodiak Sciences
$51.09

21.39 (72.02%)

02/20/19
02/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kodiak Sciences (KOD) initiated with a Buy at Chardan. 2. Veeva (VEEV) initiated with an Equal Weight at Barclays. 3. Agios Pharmaceuticals (AGIO) assumed with a Perform at Oppenheimer. 4. OrthoPediatrics (KIDS) initiated with an Outperform at JMP Securities. 5. Homology Medicines (FIXX) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
CHDN
02/20/19
INITIATION
Target $22.5
CHDN
Buy
Kodiak Sciences initiated with a Buy at Chardan
Chardan initiated Kodiak Sciences with a Buy and $22.50 price target.
KRTX Karuna Therapeutics
$75.77

3.02 (4.15%)

11/21/19
WEDB
11/21/19
NO CHANGE
Target $134
WEDB
Outperform
Karuna Therapeutics price target raised to $134 from $38 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Karuna Therapeutics to $134 from $38 and maintained an Outperform rating after the company reported positive topline results from its Phase 2 trial of KarXT for the treatment of acute psychosis in patients with schizophrenia, saying KarXT met the primary endpoint of mean reduction in total PANSS score compared to placebo and demonstrated statistically significant reductions in key secondary endpoints of PANSS-Positive and PANSS-Negative scores along with tolerable side effects. In a research note to investors, Moussatos says that due to KarXT likely becoming a blockbuster, she believes Karuna is likely to become an acquisition target in 2020.
07/23/19
WEDB
07/23/19
INITIATION
Target $38
WEDB
Outperform
Karuna Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Karuna Therapeutics with an Outperform rating and a $38 price target. The analyst considers Karuna Therapeutics to be an opportunity to invest in a breakthrough oral treatment for symptoms and cognitive impairment associated with schizophrenia and Alzheimer's disease as well as pain. Due to millions of schizophrenia and Alzheimer's disease patients and low compliance for current "dirty" drugs available for psychosis and nothing approved for negative symptoms or cognitive impairment, Moussatos sees blockbuster sales potential for KarXT. Starting with U.S. launch in 2023, she estimates KarXT could achieve over $1B in gross peak annual sales in 2027 and more than $4B in 2030.
11/18/19
SBSH
11/18/19
NO CHANGE
Target $115
SBSH
Buy
Karuna Therapeutics price target raised to $115 from $28 at Citi
Citi analyst Mohit Bansal said the phase 2 data reported by Karuna Therapeutics for KarXT appear better than expected, better than current anti-psychotics, and could be "paradigm changing." The drug's "benign" safety lead him to see the potential for use as a front line agent as well, leading the analyst to raise his peak unadjusted sales estimate in schizophrenia to $4.7B from $2.3B. Given the higher peak sales potential, and higher odds assigned for the drug's approval, Bansal raised his price target for Karuna shares to $115 from $28. The analyst, who thinks there is more upside in the stock despite today's move, keeps a Buy rating on Karuna shares, which are up $64.52, or 365%, to $82.20.
11/18/19
GSCO
11/18/19
NO CHANGE
Target $109
GSCO
Buy
Karuna Therapeutics price target raised to $109 from $35 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised his view on the odds of success of KarXT for the treatment of acute psychosis in patients with schizophrenia to 60% from 15% after Karuna Therapeutics announced results from its Phase 2 clinical trial of the drug. In his view, the strong signal of efficacy coupled with the drug's tolerability profile support use of KarXT in schizophrenia psychosis and have a positive read-through to the pipeline for Alzheimer's disease psychosis, Richter tells investors. He keeps a Buy rating on Karuna shares and raised his price target on the stock to $109 from $35.
CCC Clarivate Analytics
$17.92

-0.08 (-0.44%)

07/18/19
07/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sysco (SYY) initiated with an Underweight at Consumer Edge. 2. Sonim (SONM) initiated with a Buy at B. Riley FBR. 3. Ingevity (NGVT) initiated with an Outperform at BMO Capital. 4. Clarivate Analytics (CCC) initiated with a Neutral at Citi. 5. Photronics (PLAB) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/19
SBSH
07/18/19
INITIATION
Target $17
SBSH
Neutral
Clarivate Analytics initiated with a Neutral at Citi (yesterday)
Citi analyst Ashwin Shirvaikar yesterday initiated coverage of Clarivate Analytics with a Neutral rating and $17 price target. The analyst recommends waiting for a better entry point.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/19
STFL
11/11/19
INITIATION
Target $18
STFL
Hold
Clarivate Analytics initiated with a Hold at Stifel
Stifel analyst Shlomo Rosenbaum initiated coverage of Clarivate Analytics with a Hold rating and $18 price target. While he likes the company's unique assets and market positioning and sees significant room for operational upside, he also believes the operational improvement over the near-term has been captured by the stock's advance over the year, Rosenbaum tells investors.
TUFN Tufin
$19.07

-0.13 (-0.68%)

11/18/19
DADA
11/18/19
INITIATION
Target $22
DADA
Buy
DA Davidson says Tufin has 'number of catalysts' to drive growth
As reported earlier, DA Davidson analyst Andrew Nowinski initiated coverage of Tufin with a Buy rating and $22 price target. Nowinski said the company has a "number of catalysts" to drive growth, including the continued adoption of the automation products and the resulting growth in big deals. Longer-term, the analyst sees an opportunity for growth to continue, driven by the adoption of the new cloud-based solutions.
11/18/19
DADA
11/18/19
INITIATION
DADA
Buy
Tufin initiated with a Buy at DA Davidson
DA Davidson analyst Andrew Nowinski initiated coverage of Tufin with a Buy rating.
06/13/19
JEFF
06/13/19
NO CHANGE
Target $28
JEFF
Buy
Tufin Q1 earnings beat should flow into Q2, says Jefferies
Jefferies analyst John DiFucci kept his Buy rating and $28 price target on Tufin after its "solid" Q1 earnings beat, saying the performance should also flow into Q2 as its license agreements accelerated slightly from the prior period. The analyst maintains his view that the company has a "vast opportunity", even though its next couple of years should be "investment years."
09/03/19
JEFF
09/03/19
NO CHANGE
Target $28
JEFF
Buy
Tufin in 'pole position' with SecureChange, says Jefferies
Jefferies analyst John DiFucci kept his Buy rating and $28 price target on Tufin after its Q2 earnings beat and in-line Q3 guidance, saying the quarter was marked by several seven-figure deals, including new commitments by new logos and expansions. The analyst is positive on Tufin's SecureChange product, calling it a "compelling differentiator" for a company that is in a pole position within a "huge, untapped opportunity of security policy orchestration".
ARWR Arrowhead
$63.33

-9.65 (-13.22%)

11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform after Medicines Company takeover at Baird
As previously reported, Baird analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals (ARWR) to Outperform from Neutral with a price target of $70, up from $39, after Medicines Company (MDCO) announced a definitive agreement to be acquired by Novartis (NVS). That deal forces Kumar to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease, the analyst tells investors. Given the early positive efficacy for Arrowhead's ANGPTL3 and APOC3 RNAi drugs presented at the American Heart Association meeting, Kumar believes these programs have "the chance to dominate the ANGPTL3 and APOC3 landscapes," though cautions both are "quite early."
11/25/19
11/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deckers Brands (DECK) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying the stock's upside guidance potential amid improving weather outlook for the 2nd half of FY20 and also cites the company's "compelling" portfolio structure along with its "cash cow" UGG brand. 2. Wendy's (WEN) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying he left recent management meetings with greater confidence in the company's sales and EBITDA drivers over the next few years, especially the breakfast launch planned for 2020. 3. Hasbro (HAS) upgraded to Buy from Neutral at UBS with analyst Arpine Kocharyan saying expectations for the company have seen a "meaningful reset" after a weak Q3 results, but he sees upside in the stock thanks to the better than expected revenue and the cost synergies from Entertainment One acquisition, along with the momentum of its gaming portfolio. 4. Nvidia (NVDA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Joseph Moore saying both of Nvidia's gaming and data center segments fell short of expectations over the course of 2019, but investments made this year in the gaming business should pay off in 2020 while recent Cloud commentary indicates that the inflection in "conversational AI" is real and new Nvidia products should ease concerns about competition in the data center segment. 5. Arrowhead (ARWR) upgraded to Outperform from Neutral at Baird with analyst Madhu Kumar saying Medicines Company's (MDCO) announcement of a definitive agreement to be acquired by Novartis (NVS) forces him to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/19
PIPR
11/26/19
NO CHANGE
Target $72
PIPR
Overweight
Arrowhead price target raised to $72 from $54 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $72 from $54 and reiterates an Overweight rating on the shares following last night's results. The company expects to have three pivotal Phase III trials underway in 2020, Tenthoff tells investors in a research note. He believes Arrowhead's RNAi will address both orphan and broader cardiovascular indications characterized by high triglycerides.
11/27/19
RILY
11/27/19
NO CHANGE
Target $83
RILY
Buy
Arrowhead price target raised to $83 from $59 at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani raised his price target for Arrowhead Pharmaceuticals to $83 from $59 while maintaining a Buy rating on the shares. The analyst believes the company has built a "unique" position in RNAi-based therapies.
CWEN Clearway Energy
$19.28

0.09 (0.47%)

07/19/19
BOFA
07/19/19
UPGRADE
BOFA
Buy
Clearway Energy upgraded to Buy from Neutral at BofA/Merrill
02/20/19
EVER
02/20/19
DOWNGRADE
EVER
In Line
Clearway Energy downgraded to In Line from Outperform at Evercore ISI
10/28/19
WOLF
10/28/19
DOWNGRADE
Target $19
WOLF
Peer Perform
Clearway Energy downgraded to Peer Perform on PG&E risk at Wolfe Research
Wolfe Research analyst Steve Fleishman downgraded Clearway Energy (CWEN) to Peer Perform from Outperform with a price target of $19, down from $21. The analyst notes Clearway has the most exposure to PG&E (PCG) with 30% of consolidated CAFD derived from the company.
04/30/19
MSCO
04/30/19
NO CHANGE
MSCO
Clearway, Pattern Energy could see boost on Atlantica news, says Morgan Stanley
Morgan Stanley analyst Stephen Byrd noted that Atlantica Yield (AY) has announced plans to explore strategic options and while he has no knowledge of any talks involving any of the companies he covers in the space he believes that the market could begin to price in potential strategic optionality at other YieldCos. If so, he sees the potential for modest upside for Clearway Energy (CWEN) and Pattern Energy (PEGI), depending on a what assumptions the market makes, Byrd tells investors. He also points to NextEra Energy Partners (NEP) as a "special case" among YieldCos, stating that its dividend yield is much lower, but its growth prospects are significantly better. In the case of NextEra, though, Byrd said he sees potential downside given the relatively high amount of non-amortizing leverage at parent NextEra Energy (NEE).

TODAY'S FREE FLY STORIES

ERJ

Embraer

$17.79

-0.04 (-0.22%)

11:02
12/10/19
12/10
11:02
12/10/19
11:02
Hot Stocks
Embraer signs order with Congo Airways for 2 E175 jets »

Embraer and Congo Airways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$33.90

-0.875 (-2.52%)

, UBER

Uber

$27.89

0.18 (0.65%)

10:50
12/10/19
12/10
10:50
12/10/19
10:50
On The Fly
Analysts say controversial Peloton TV ad 'actually increases' brand awareness »

Pelton Interactive (PTON)…

PTON

Peloton

$33.90

-0.875 (-2.52%)

UBER

Uber

$27.89

0.18 (0.65%)

SDC

SmileDirectClub

$8.32

0.08 (0.97%)

LYFT

Lyft

$45.61

0.2 (0.44%)

WORK

Slack Technologies

$22.65

-0.34 (-1.48%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CONN

Conn's

$14.77

-5.74 (-27.99%)

10:45
12/10/19
12/10
10:45
12/10/19
10:45
Hot Stocks
Conn's says CECL adoption to lead to 40%-60% increase in provisions »

Conn's says the CECL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

VOD

Vodafone

$18.79

-0.085 (-0.45%)

10:45
12/10/19
12/10
10:45
12/10/19
10:45
Options
Vodafone call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/10/19
12/10
10:45
12/10/19
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

10:45
12/10/19
12/10
10:45
12/10/19
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

10:45
12/10/19
12/10
10:45
12/10/19
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

10:45
12/10/19
12/10
10:45
12/10/19
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

BPOP

Popular

$57.11

1.07 (1.91%)

10:43
12/10/19
12/10
10:43
12/10/19
10:43
Hot Stocks
Popular says Raging Capital letter shared with board, seeks 'open dialogue' »

Popular confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GFL

GFL Environmental

$0.00

(0.00%)

10:41
12/10/19
12/10
10:41
12/10/19
10:41
Hot Stocks
GFL Environmental to acquire County Waste of Virginia; terms not disclosed »

GFL Environmental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$347.25

7.78 (2.29%)

10:38
12/10/19
12/10
10:38
12/10/19
10:38
Recommendations
Tesla analyst commentary  »

Tesla price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 07

    Jan

AXTA

Axalta Coating

$29.81

-0.41 (-1.36%)

10:35
12/10/19
12/10
10:35
12/10/19
10:35
Options
Axalta Coating put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
12/10/19
12/10
10:30
12/10/19
10:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NLOK

NortonLifeLock

$26.29

0.86 (3.38%)

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Options
NortonLifeLock call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
UBS alternative energy windham to hold an analyst/industry conference call »

Alternative Energy &…

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
JPMorgan oil & gas analysts to hold an analyst/Industry conference call »

Large Cap Oil & Gas…

OMCL

Omnicell

$80.19

0.16 (0.20%)

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
Omnicell to host investor & analyst day »

Investor & analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

QSR

Restaurant Brands

$66.80

0.8 (1.21%)

, MCD

McDonald's

$194.64

-0.07 (-0.04%)

10:19
12/10/19
12/10
10:19
12/10/19
10:19
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

QSR

Restaurant Brands

$66.80

0.8 (1.21%)

MCD

McDonald's

$194.64

-0.07 (-0.04%)

SBUX

Starbucks

$87.36

1.08 (1.25%)

WEN

Wendy's

$21.59

-0.13 (-0.60%)

CMG

Chipotle

$822.75

-4.81 (-0.58%)

DNKN

Dunkin' Brands

$76.03

-0.2 (-0.26%)

EAT

Brinker

$41.77

-0.92 (-2.16%)

DPZ

Domino's Pizza

$286.82

0.23 (0.08%)

YUM

Yum! Brands

$98.95

-0.04 (-0.04%)

TXRH

Texas Roadhouse

$55.93

-0.22 (-0.39%)

ARAV

Aravive

$12.19

0.89 (7.88%)

BORR

Borr Drilling

$6.80

0.2 (3.03%)

AAXN

Axon

$72.49

0.22 (0.30%)

ZM

Zoom Video

$64.98

-0.94 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

  • 16

    Dec

NFLX

Netflix

$295.83

-6.65 (-2.20%)

, JPM

JPMorgan

$133.55

-0.9 (-0.67%)

10:18
12/10/19
12/10
10:18
12/10/19
10:18
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

NFLX

Netflix

$295.83

-6.65 (-2.20%)

JPM

JPMorgan

$133.55

-0.9 (-0.67%)

MKC

McCormick

$170.54

-2.155 (-1.25%)

CSX

CSX

$69.59

-0.82 (-1.16%)

VTR

Ventas

$56.78

-0.72 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

PH

Parker-Hannifin

$201.96

0.49 (0.24%)

, RDFN

Redfin

$20.98

0.21 (1.01%)

10:18
12/10/19
12/10
10:18
12/10/19
10:18
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

PH

Parker-Hannifin

$201.96

0.49 (0.24%)

RDFN

Redfin

$20.98

0.21 (1.01%)

MNRO

Monro

$78.70

4.24 (5.69%)

AGRO

Adecoagro

$7.98

0.47 (6.26%)

OI

Owens-Illinois

$10.51

0.22 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/10/19
12/10
10:17
12/10/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/10/19
12/10
10:16
12/10/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LK

Luckin Coffee

$30.72

0.35 (1.15%)

10:15
12/10/19
12/10
10:15
12/10/19
10:15
Options
Luckin Coffee put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTT

Qutoutiao

$2.70

-0.16 (-5.59%)

10:14
12/10/19
12/10
10:14
12/10/19
10:14
Hot Stocks
Qutoutiao sinks after short report claims 74% of sales are 'fake' »

Shares of Qutoutiao moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$43.80

0.515 (1.19%)

10:12
12/10/19
12/10
10:12
12/10/19
10:12
Conference/Events
Smartsheet management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.